20.01.2021 • News

Angelini Acquires Arvelle Therapeutics

Italy’s Angelini Pharma has entered into an agreement to acquire Swiss biopharma Arvelle Therapeutics in an all-cash transaction worth up to $960 million. The first $610 million will be paid following regulatory clearance of the deal, with a further $350 million paid if Arvelle’s epilepsy treatment cenobamate achieves certain revenue targets.

Arvelle is focused on developing treatments for patients suffering from central nervous system (CNS) disorders. In February 2019, it entered into an exclusive licensing agreement with SK Biopharmaceuticals to develop and commercialize anti-seizure medication cenobamate in Europe. The treatment has already been approved for partial-onset seizures in adults in the US, where it is commercially available under the brandname Xcopri. 

The Korean company owns 12% of Arvelle and has agreed to sell its stake to Angelini.

Once the transaction has closed, Angelini will have the exclusive license to commercialize cenobamate in the EU as well as in Switzerland and the UK.  The European Medicines Agency is expected to approve the therapy this year.

“This transaction will propel us into a leading European player, well positioned to address the needs of patients with different Central Nervous System (CNS) disorders through an innovative portfolio, distinctive medical capabilities and extensive commercial presence, also via the opening of direct affiliates in France, UK, Nordics and Switzerland by 2022,” said Pierluigi Antonelli, Angelini Pharma’s CEO.

Angelini Pharma is focused on therapies for mental health (including pain), rare diseases and consumer healthcare. In March 2020, the Rome-headquartered firm acquired GlaxoSmithKline’s ThermaCare global business rights, excluding North America. The deal included a dedicated manufacturing site for ThermaCare products in Albany, Georgia, USA.

ThermaCare uses patented technology to produce heat to help rebuild damaged tissue and accelerate healing. Heat therapy is widely known to help ease muscle pain, reduce soreness and loosen tight muscles.

Author: Elaine Burridge, Freelance Journalist

Angelini Pharma has agreed to acquire Arvelle Therapeutics for up to $960...
Angelini Pharma has agreed to acquire Arvelle Therapeutics for up to $960 million. Focused on developing treatments for central nervous system disorders, Arvelle has an exclusive license to commercialize SK Biopharmaceuticals anti-seizure medication cenobamate in Europe. (c) joshua coleman

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read